JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB100568

Human IL-29 ELISA Kit

Be the first to review this product! Submit a review

|

(3 Publications)

Human IL-29 ELISA Kit is a sandwich ELISA designed to quantify Human IL-29 with a sensitivity of 20 pg/mL.

- Colorimetric sandwich ELISA - 450 nm readout - works on any plate reader
- Wide dynamic range - quantifies 13.72 - 10000 pg/mL

View Alternative Names

IL29, ZCYTO21, IFNL1, Interferon lambda-1, IFN-lambda-1, Cytokine Zcyto21, Interleukin-29, IL-29

3 Images
Sandwich ELISA - Human IL-29 ELISA Kit (AB100568)
  • sELISA

Unknown

Sandwich ELISA - Human IL-29 ELISA Kit (AB100568)

Representative standard curve using ab100568

Sandwich ELISA - Human IL-29 ELISA Kit (AB100568)
  • sELISA

Unknown

Sandwich ELISA - Human IL-29 ELISA Kit (AB100568)

Representative standard curve using ab100568

Sandwich ELISA - Human IL-29 ELISA Kit (AB100568)
  • sELISA

Unknown

Sandwich ELISA - Human IL-29 ELISA Kit (AB100568)

IL-29 measured in biological fluids, background signal subtracted (duplicates +/- SD).

Key facts

Detection method

Colorimetric

Sample types

Plasma, Cell culture supernatant, Serum

Reacts with

Human

Assay type

Sandwich (quantitative)

Sensitivity

< 20 pg/mL

Range

13.72 - 10000 pg/mL

Assay Platform

Microplate

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "sELISA": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }

Product details

Human IL-29 ELISA Kit ab100568 is a sandwich ELISA to measure Human IL-29 in serum, plasma, cell culture supernatant with a sensitivity of 20 pg/ml.

How the assay works

This assay employs an antibody specific for Human IL-29 coated on a 96-well plate. Standards and samples are pipetted into the wells and IL-29 present in a sample is bound to the wells by the immobilized antibody. The wells are washed and biotinylated anti-Human IL-29 antibody is added. After washing away unbound biotinylated antibody, HRP-conjugated streptavidin is pipetted to the wells. The wells are again washed, a TMB substrate solution is added to the wells and color develops in proportion to the amount of IL-29 bound. The Stop Solution changes the color from blue to yellow, and the intensity of the color is measured at 450 nm.

Assay Specificity

Our ELISA kits are rigorously validated to ensure the highest level of consistency and reproducibility. Please check the protocol booklet for more details

Human IL-29 ELISA Kit ab100568 protocol summary

1. Add standard or sample to each well used. Incubate at room temperature
2. Wash and add prepared biotinylated antibody to each well. Incubate at room temperature.
3. Wash and add prepared streptavidin solution. Incubate at room temperature.
4. Add TMB Development Solution to each well. Incubate at room temperature.
5. Add Stop Solution to each well. Read at 450nm immediately.

Optimization may be required with urine samples.

Recovery

[ { "sample": "Cell culture supernatant", "range": "104 - 143 %", "average": "= 124" }, { "sample": "Serum", "range": "87 - 105 %", "average": "= 97.78" }, { "sample": "Plasma", "range": "95 - 145 %", "average": "= 112.7" } ]

What's included?

{ "values": { "1x96Tests": { "sellingSize": "1 x 96 Tests", "publicAssetCode":"ab100568-1x96Tests", "assetComponentDetails": [ { "size":"1 x 25 mL", "name":"20X Wash Buffer", "number":"AB100568-CMP03", "productcode":"" }, { "size":"1 x 8 mL", "name":"Stop Solution", "number":"AB100568-CMP07", "productcode":"" }, { "size":"1 x 12 mL", "name":"TMB One-Step Substrate Reagent", "number":"AB100568-CMP08", "productcode":"" }, { "size":"1 x 200 µL", "name":"200X HRP-Streptavidin Concentrate", "number":"AB100568-CMP04", "productcode":"" }, { "size":"2 x 1 Vial", "name":"Recombinant Human IL-29 Standard (lyophilized)", "number":"AB100568-CMP02", "productcode":"" }, { "size":"1 x 1 Unit", "name":"IL-29 Microplate (12 x 8 wells)", "number":"AB100568-CMP01", "productcode":"" }, { "size":"2 x 1 Vial", "name":"Biotinylated anti-Human IL-29", "number":"AB100568-CMP09", "productcode":"" }, { "size":"1 x 30 mL", "name":"Assay Diluent C", "number":"AB100568-CMP06", "productcode":"" }, { "size":"1 x 15 mL", "name":"5X Assay Diluent B", "number":"AB100568-CMP05", "productcode":"" } ] } } }

Properties and storage information

Shipped at conditions
Blue Ice
Appropriate short-term storage conditions
-20°C
Appropriate long-term storage conditions
-20°C
Storage information
-20°C

Product protocols

Target data

Cytokine with antiviral, antitumour and immunomodulatory activities. Plays a critical role in the antiviral host defense, predominantly in the epithelial tissues. Acts as a ligand for the heterodimeric class II cytokine receptor composed of IL10RB and IFNLR1, and receptor engagement leads to the activation of the JAK/STAT signaling pathway resulting in the expression of IFN-stimulated genes (ISG), which mediate the antiviral state. Has a restricted receptor distribution and therefore restricted targets : is primarily active in epithelial cells and this cell type-selective action is because of the epithelial cell-specific expression of its receptor IFNLR1. Exerts an immunomodulatory effect by up-regulating MHC class I antigen expression.
See full target information IFNL1

Publications (3)

Recent publications for all applications. Explore the full list and refine your search

Nature communications 16:6040 PubMed40593852

2025

Oropouche virus infects human trophoblasts and placenta explants.

Applications

Unspecified application

Species

Unspecified reactive species

Christina J Megli,Rebecca K Zack,Jackson J McGaughey,Ryan M Hoehl,Taylor Snisky,Amy L Hartman,Cynthia M McMillen

EMBO reports 25:3777-3788 PubMed39060455

2024

Mucosal IFNλ1 mRNA-based immunomodulation effectively reduces SARS-CoV-2 induced mortality in mice.

Applications

Unspecified application

Species

Unspecified reactive species

Anna Macht,Yiqi Huang,Line S Reinert,Vincent Grass,Kristin Lohmer,Elke Tatjana Aristizabal Prada,Eveline Babel,Alexandra Semmler,Wen Zhang,Andrea Wegner,Eva Lichtenegger-Hartl,Sonja Haas,Günther Hasenpusch,Steffen Meyer,Søren R Paludan,Andreas Pichlmair,Carsten Rudolph,Thomas Langenickel

Journal of virology 98:e0098324 PubMed39016561

2024

Vaccine strains of Rift Valley fever virus exhibit attenuation at the maternal-fetal placental interface.

Applications

Unspecified application

Species

Unspecified reactive species

Cynthia M McMillen,Christina Megli,Rebecca Radisic,Lauren B Skvarca,Ryan M Hoehl,Devin A Boyles,Jackson J McGaughey,Brian H Bird,Anita K McElroy,Amy L Hartman
View all publications
websiteProtocolBooklet
en

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com